We don’t know if the psychedelic trip is necessary for psychiatric benefit from hallucinogens.

A trip may loosen rigid brain networks, but plasticity alone isn’t automatically therapeutic.

Animal studies suggest that antidepressant effects with hallucinogens can occur without the trip.

Only human trials can tell us what’s lost—or gained—when the psychedelic trip is removed.

One question may determine whether psychedelics ever move from specialized research centers into psychiatric offices. Does the patient need to trip for the treatment to work?

This is not a minor issue. Hallucinations are unpredictable. Increasing brain plasticity is not automatically therapeutic. Psychedelics may open a therapeutic window, but they cannot control what comes through. Selecting the right patient, preparation, setting, safety and monitoring, therapy, and follow-up may determine how much the experience helps. All of that is much more involved and costly than prescribing a pill.

Psychedelics are moving toward mainstream psychiatry, led by psilocybin for depression. Clinical trials use synthetic psilocybin with a known dose and purity—not an unpredictable mushroom. But standardized psilocybin is still a hallucinogen.

Scientists may have managed to strip the hallucinations away from therapeutic compounds in animal studies, but it is not looking that simple for humans. In clinical trials, patients who have the strongest, most meaningful trips usually see the best results. That doesn’t automatically mean the trip is causing the cure, but it makes it pretty hard to argue that the experience doesn’t matter.

In a 2026 Nature Medicine article, NYU’s Josh Siegel and his colleagues proposed a two-stage model. First, the psychedelic disturbs the brain’s usual organization. Then it opens a temporary period of increased plasticity, when learning and change may become easier.

Psilocybin is rapidly converted to psilocin, which activates serotonin 5-HT2A receptors, particularly on cortical pyramidal neurons. An international analysis of 11 imaging datasets involving five psychedelics found increased communication between higher-order networks and systems controlling sensation and movement. The brain’s usual boundaries became less rigid.

For a depressed patient, that disruption may make the depressed brain less certain that its glass-empty view of the world is the only possible one. Not being depressed becomes imaginable. But what produced the improvement: the neurobiology, the trip, or both?

Clinical Evidence and the Blinding Problem

In a 2026 Maudsley NHS trial, 60 patients with treatment-resistant depression received either 25 mg of COMP360 psilocybin or placebo, along with preparation, dosing support, and integration. After three weeks, the psilocybin group improved by 10.41 points more on the Montgomery-Åsberg Depression Rating Scale. Benefits persisted at six weeks. Impressive. But every patient who received psilocybin correctly guessed that they had received the drug—so much for blinding.

Stacey Armstrong’s 2026 open-label pilot study treated 12 veterans with severe, treatment-resistant PTSD. They received two psilocybin sessions surrounded by approximately 16 hours of preparation and integration therapy. Nine were in remission one month later. Again, impressive. But symptoms had already started improving during preparation. Patients who improved more before receiving psilocybin also did better afterward. The open study supports psilocybin treatment but can’t tell us which part worked—or whether the trip was essential.

We Have Tried This Before

Psychiatry has pursued a similar goal with electroconvulsive therapy (ECT): keep its remarkable antidepressant effect while reducing memory loss, cognitive burden, anesthesia requirements, and fear. Modern anesthesia, unilateral electrode placement, and ultrabrief-pulse stimulation have made ECT safer and easier to tolerate. But its extraordinary efficacy has not been reproduced without inducing a therapeutic seizure.

ECT taught us an important lesson: Keeping the cure while removing the cost is harder than it sounds.

Can Chemistry Keep the Medicine and Lose the Trip?

A 2025 meta-analysis found that the intensity of the psychedelic experience was associated with greater clinical improvement, especially in mood disorders. But association is not causation.

A 2026 study from David Olson’s group at UC Davis........

© Psychology Today